2026-01-29 - Analysis Report
**Company Overview**
Thermo Fisher Scientific is a multinational biotechnology product development company that specializes in serving the fields of pharmaceutical, clinical research, industrial, and applied markets.

**Return Rate Comparison**

* Cumulative return of review stock (TMO): 109.35%
* Cumulative return of comparison stock (S&P 500, VOO): 128.51%
* Divergence: -19.20 (difference in cumulative return on the last day of the data)
* Relative divergence: 28.60% (current position when the minimum-maximum fluctuation range is set to 100)

**Alpha, Beta Analysis**

*| Year | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 30.0% | 17.2% | 21.0% | 1.1 | 82.1B |
| 2017-2019  | 67.0% | 17.2% | 42.0% | 1.1 | 119.2B |
| 2018-2020  | 80.0% | 23.7% | 56.0% | 0.8 | 170.9B |
| 2019-2021  | 144.0% | 23.7% | 80.0% | 0.8 | 244.8B |
| 2020-2022  | 50.0% | 23.7% | 45.0% | 0.8 | 202.0B |
| 2021-2023  | -48.0% | 26.2% | -66.0% | 0.9 | 194.7B |
| 2022-2024  | -66.0% | 24.5% | -95.0% | 0.9 | 190.9B |
| 2023-2025  | -29.0% | 34.3% | -104.0% | 0.8 | 212.6B |

**Recent Stock Price Fluctuations**

* Close: $623.91
* Last-market: {'price': 609.315, 'previousClose': 623.91, 'change': -2.34}
* 5-day SMA: $630.45
* 20-day SMA: $613.70
* 60-day SMA: $588.22

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence, Expected_Return Analysis**

* Market Risk Indicator (MRI): 0.70 (0.9~1.0: High Investment Recommended, 0.7~0.9: Medium Investment, 0.4~0.7: Low Investment, <0.4: Very Risky)
* RSI: 51.60
* PPO: -0.02
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.70)
* Recent (20 days) relative divergence change: -2.30 (-): worsening
* 7-day Rank change: 10 (+): rank up
* 7-day Dynamic Expected Return change: 83.50 (+): improving
* Expected Return (%): 51.00%

**Recent News & Significant Events**

* [2026-01-28] Thermo Fisher Scientific (TMO) Valuation Check After Recent Share Price Momentum - Yahoo Finance
* [2026-01-27] THERMO FISHER SCIENTIFIC Q4 2025 Earnings Preview: Recent $TMO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
* [2026-01-27] Is Thermo Fisher Scientific (TMO) Pricing Reflecting Recent Steady Returns And Growth Expectations - simplywall.st
* [2026-01-13] Thermo Fisher wins contracts as pharma shifts production to US, CEO says - Reuters
* [2026-01-27] Thermo Fisher Scientific Inc. $TMO Shares Purchased by Chilton Capital Management LLC - MarketBeat
* [2026-01-28] Thermo Fisher (TMO) Q4 Earnings: What To Expect - FinancialContent

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.54 (~Buy)
- Opinions: 23
- Target Price (avg/high/low): 652.61 / 750.00 / 575.00

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-31 | 4.28 | 11.12 B$ |
| 2025-08-01 | 4.28 | 10.86 B$ |
| 2025-05-02 | 3.99 | 10.36 B$ |
| 2024-11-01 | 4.26 | 10.60 B$ |
| 2025-10-31 | 4.26 | 10.60 B$ |

The earnings per share (EPS) has been relatively stable over the past few quarters, ranging from 3.99 to 4.28. The revenue has also been consistent, with a slight decrease in the second quarter of 2025.

**Financial Information**

### Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.12B | 41.21% |
| 2025-06-30 | $10.85B | 40.61% |
| 2025-03-31 | $10.36B | 40.86% |
| 2024-12-31 | $11.39B | 42.32% |
| 2024-09-30 | $10.60B | 40.84% |

The revenue has been steadily increasing over the past few quarters, with a slight decrease in the second quarter of 2025. The profit margin has also been relatively consistent, ranging from 40.61% to 42.32%.

### Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.02B | 3.17% |
| 2025-06-30 | $50.51B | 3.20% |
| 2025-03-31 | $49.39B | 3.05% |
| 2024-12-31 | $49.59B | 3.69% |
| 2024-09-30 | $48.99B | 3.33% |

The equity has been consistently increasing over the past few quarters, while the return on equity (ROE) has been relatively stable, ranging from 3.05% to 3.69%.

### Comprehensive Analysis (Summary of previous items)

Thermo Fisher Scientific (TMO) has a relatively stable earnings per share (EPS) and a consistent revenue stream. The profit margin has been relatively consistent over the past few quarters, ranging from 40.61% to 42.32%. The equity has been consistently increasing, while the return on equity (ROE) has been relatively stable. The risk level is medium, based on the market risk indicator (MRI) of 0.70. The cumulative return of TMO has been lower compared to the S&P 500, but the divergence has been decreasing. The hybrid signal is buy, and the expected return is 51.00%. Overall, TMO has shown relatively stable financial performance and a consistent revenue stream.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.